PON1 Q192R and clopidogrel: a case of the winner's curse or inadequate replication?

Talameh, J A; McLeod, H L

Talameh, J A; McLeod, H L.

Affiliation

Talameh JA; UNC Institute for Pharmacogenomics and Individualized Therapy, Division of Pharmacotherapy and Experimental Therapeutics, University of North Carolina at Chapel Hill, North Carolina, USA.

Clin Pharmacol Ther ; 90(6): 771-4, 2011 Dec.

Article in En | MEDLINE | ID: mdl-22089342

ABSTRACT

ABSTRACT

The antiplatelet drug clopidogrel is one of the most commonly prescribed drugs in the world, but there is wide interpatient variability in its antiplatelet effects. The majority of this variation is due to genetic effects, but there is controversy over which genetic variants are important and their relative contribution. This controversy may stem from the genetic association research paradigm, which casts the "winner's curse."

Subject(s)

Aryldialkylphosphatase/genetics; Cardiovascular Diseases/genetics; Cardiovascular Diseases/mortality; Genetic Association Studies/methods; Genetic Variation/genetics; Myocardial Infarction/drug therapy; Myocardial Infarction/genetics; Polymorphism, Genetic/genetics; Ticlopidine/analogs & derivatives; Female; Humans; Male

Fulltext

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Polymorphism, Genetic / Genetic Variation / Ticlopidine / Cardiovascular Diseases / Aryldialkylphosphatase / Genetic Association Studies / Myocardial Infarction Limits: Female / Humans / Male Language: En Journal: Clin Pharmacol Ther Year: 2011 Document type: Article

Fulltext

XML

PubMed Links

Search on Google